Antibiotic Consumption and Healthcare-Associated Infections Caused by Multidrug-Resistant Gram-Negative Bacilli at a Large Medical Center in Taiwan from 2002 to 2009: Implicating the Importance of Antibiotic Stewardship

I-Ling Chen1,2,*, Chen-Hsiang Lee2,3,4,*, Li-Hsiang Su2, Ya-Feng Tang2, Shun-Jen Chang5, Jien-Wei Liu2,3,4*

1 Department of Pharmacology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 2 Infection Control, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 3 Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 4 Chang Gung University College of Medicine, Kaohsiung, Taiwan, 5 Department of Kinesiology, Health and Leisure Studies, National University of Kaohsiung, Kaohsiung, Taiwan

Abstract

Background: Better depicting the relationship between antibiotic consumption and evolutionary healthcare-associated infections (HAIs) caused by multidrug-resistant Gram-negative bacilli (MDR-GNB) may help highlight the importance of antibiotic stewardship.

Methodology/Principal Findings: The correlations between antibiotic consumption and MDR-GNB HAIs at a 2,700-bed primary care and tertiary referral center in Taiwan between 2002 and 2009 were assessed. MDR-GNB HAI referred to a HAI caused by MDR-Enterobacteriaceae, MDR-Pseudomonas aeruginosa or MDR-Acinetobacter spp.. Consumptions of individual antibiotics and MDR-GNB HAI series were first evaluated for trend over time. When a trend was significant, the presence or absence of associations between the selected clinically meaningful antibiotic resistance and antibiotic consumption was further explored using cross-correlation analyses. Significant major findings included (i) increased consumptions of extended-spectrum cephalosporins, carbapenems, aminopenicillins/β-lactamase inhibitors, piperacillin/tazobactam, and fluoroquinolones; (ii) decreased consumptions of non-extended-spectrum cephalosporins, natural penicillins, aminopenicillins, ureidopenicillin and aminoglycosides; and (iii) decreasing trend in the incidence of the overall HAIs, stable trends in GNB HAIs and MDR-GNB HAIs throughout the study period, and increasing trend in HAIs caused by carbapenem-resistant (CR) Acinetobacter spp. since 2006. HAIs due to CR-Acinetobacter spp. was found to positively correlate with the consumptions of carbapenems, extended-spectrum cephalosporins, aminopenicillins/β-lactamase inhibitors, piperacillin/tazobactam and fluoroquinolones, and negatively correlate with the consumptions of non-extended-spectrum cephalosporins, penicillins and aminoglycosides. No significant association was found between the increased use of piperacillin/tazobactam and increasing HAIs due to CR-Acinetobacter spp..

Conclusions: The trend in overall HAIs decreased and trends in GNB HAIs and MDR-GNB HAIs remained stable over time suggesting that the infection control practice was effective during the study period, and the escalating HAIs due to CR-Acinetobacter spp. were driven by consumptions of broad-spectrum antibiotics other than piperacillin/tazobactam. Our data underscore the importance of antibiotic stewardship in the improvement of the trend of HAIs caused by Acinetobacter spp..

Citation: Chen I-L, Lee C-H, Su L-H, Tang Y-F, Chang S-J, et al. (2013) Antibiotic Consumption and Healthcare-Associated Infections Caused by Multidrug-Resistant Gram-Negative Bacilli at a Large Medical Center in Taiwan from 2002 to 2009: Implicating the Importance of Antibiotic Stewardship. PLoS ONE 8(5): e65621. doi:10.1371/journal.pone.0065621

Editor: Qijing Zhang, Iowa State University, United States of America

Received: October 31, 2012; Accepted: April 25, 2013; Published: May 30, 2013

Copyright: © 2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was partially supported by the grant NSC 97-2314-B-182A-028 from the National Science Council, Executive Yuan, Taipei, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Competing Interests: The authors have declared that no competing interests exist.

*E-mail: drjwliu@yahoo.com.tw

These authors contributed equally to this work.

Introduction

Infections caused by multidrug-resistant (MDR) Gram-negative bacilli (GNB) poses a threat to affected patients worldwide [1]. Some clinically important MDR-GNBs including extended-spectrum cephalosporin-resistant Enterobacteriaceae (e.g., Echerichia coli, Enterobacter species and Klebsiella pneumoniae), MDR-Pseudomonas aeruginosa, and carbapenem-resistant (CR) Acinetobacter spp. are of particular concern [2], as more than 50% of these GNB species that caused healthcare-associated infections (HAIs) have been reported to be MDR [3]. Compared with infections due to the antibiotic-susceptible GNB counterparts, MDR-GNB infec-
tions frequently lead to poorer outcomes such as longer hospital stays, increased mortality, and higher hospitalization cost [4]. It has been well documented that the selective pressure resulting from non-prudent antibiotic consumption is the major cause of the increasing emergence of MDR pathogens [1,2].

A substantial number of reports demonstrated the relationships between antibiotic consumptions and the emergences of MDR-GNB in hospital settings [3-10]. However, to our knowledge, so far there has not been a single study that specifically designed to explore the dynamics of antibiotic consumptions and the incidence of MDR-GNB HAI. The objectives of this study were (i) to understand the trends in antibiotic consumption and incidence of HAI, and (ii) to clarify the relationships between antibiotic consumptions and the evolutionary MDR-GNB HAI during an eight-year period at a large medical center in Taiwan. The implications of this study will be discussed.

Methods

This study analyzed antibiotic consumptions in adult patients and the incidences of antimicrobial resistance among clinically significant pathogens for HAI between January 2002 and December 2009 at Kaohsiung Chang Gung Memorial Hospital (KSCGMH), a 2,700-bed facility that serves as a primary care and tertiary referral center in Taiwan. The study was conducted with a waiver of informed consent from the participants, which was approved by the Institutional Review Board (Ethics Committee) of Chang Gung Memorial Hospital (Document no. 97-1694B).

Consumed oral and parenteral antibiotics that were retrieved from the electronic database of the hospital’s pharmacy for analyses included: carbapenems (imipenem, meropenem, and ertapenem), non-extended-spectrum cephalosporins (cefazolin, cefuroxime), extended-spectrum cephalosporins (ceftriaxone, cefazidime, cefpirome, and cefepime), natural penicillin (penicillin G), aminopenicillins (ampicillin and amoxicillin), ureidopenicillins (pipercillin), aminopenicillins/β-lactamase inhibitor (amoxicillin/ clavulanate and ampicillin/sulbactam), anti-pseudomonal penicillin/β-lactamase inhibitor (pipercillin/tazobactam), aminoglycosides (gentamicin and amikacin), fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin), folate pathway inhibitors (trimethoprim-sulfamethoxazole), and glycopeptides (vancomycin and teicoplanin). Antibiotic consumption was evaluated based on the defined daily dose (DDD) per 1,000 inpatient days for each prescribed antibiotic [11] and the quarterly categorized prescription to which the antibiotic belonged. The hospital inpatient days were obtained from the institute’s administrative database. The annual hospital inpatient days at KSCGMH increased from 641,212 in 2002 to 703,111 in 2009.

HAI were defined as infections that were not present and without evidence of incubation at the time of admission to KSCGMH, and were identified based on the CDC diagnostic criteria for nosocomial infections [12] at regular surveillance for HAI between January 2002 and December 2009. Specific HAI(s) and the pathogen(s) were identified according to the CDC diagnostic criteria as well, and some of the HAI were polymicrobial infections [12]. The regular surveillance of HAI during the study period at KSCGMH was performed by the same staff that consisted of senior infection-control practitioners under the supervision of a senior infectious-diseases specialist (Dr. JW Liu).

A HAI-GNB was defined as a GNB that was judged to be the pathogen of a HAI. HAI-GNBs tracked in this study included E. coli, K. pneumoniae, K. oxytoca, Enterobacter cloacae, Serratia marcescens, Proteus spp., P. aeruginosa, Acinetobacter spp., Stenotrophomonas maltophilia, and other glucose-nonfermenting GNBs (i.e., P. fluorescens, P. putida, Burkholderia cepacia, Chryseobacterium meningosepticum, G. indolgenes, and Alcaligenes spp.). MDR was defined based on the criteria proposed by Magiorakos et al. [13] with modifications. As a large number of GNBs are intrinsically multidrug-resistant, a MDR-HAI-GNB was defined in this study as a MDR-Enterobacteriaceae (other than Salmonella spp. and Shigella spp.), a MDR-P. aeruginosa, or a MDR-Acinetobacter sp. that was identified as a pathogen for HAI. A MDR-Enterobacteriaceae referred to an Enterobacteriaceae isolate that was resistant to ≥1 agent in 3 or more of the following antimicrobial classes: aminoglycosides, carbapenems, non-extended-spectrum cephalosporins, extended-spectrum cephalosporins, aminoglycosides, carbapenems, non-extended-spectrum cephalosporins, extended-spectrum cephalosporins, anti-pseudomonal penicillin/β-lactamase inhibitor, fluoroquinolones, folate pathway inhibitors, tigecycline, aminopenicillins/β-lactamase inhibitors, polymyxins, and tetracyclines [13]. A tested antibiotic profile for glucose-nonfermenting GNB adopted at KSCGMH included aminoglycosides, anti-pseudomonal carbapenems (imipenem and meropenem), anti-pseudomonal cephalosporins, anti-pseudomonal fluoroquinolines, piperacillin/tazobactam, monobactam, and polymyxins. A MDR-P. aeruginosa referred to a P. aeruginosa isolate that was resistant to ≥1 agent in 3 or more of the antibiotic classes included in the tested antibiotic profile for glucose-nonfermenting GNB [13]. A MDR-Acinetobacter sp. referred to an Acinetobacter isolate that was resistant to ≥1 agent in 3 or more of the antibiotic classes including those listed in the tested antibiotic profile for glucose-nonfermenting GNB, and extended-spectrum cephalosporins, folate pathway inhibitors, ampicillin/sulbactam, polymyxins and tigecycline [13].

As a rule, blood and/or specimen of the clinically suspicious infection site, regardless of whether the infection was acquired from hospital settings, was sampled for culture before starting antimicrobial therapy. Blood cultures were incubated in a Bactec 9240 instrument (Becton Dickinson Diagnostic Systems, Sparks, MD) at 35°C for 5 days. Specimens harvested from infection sites other than blood were inoculated in proper culture media which were then incubated at 35°C in ambient air. All plated media were examined for macroscopic evidence of bacterial growth 24h later. If no visible growth was found, the culture plates were further incubated, and the plates were examined daily for 4 consecutive days in case of culture of specimens sampled from normally sterile sites such as blood and cerebrospinal fluid [14]. All bacterial isolates were identified using biochemical tests and were then verified by a Vitek System (bioMérieux, France) using a GNI Card. The susceptibility testing was performed on a daily-service basis using Kirby-Bauer disk-diffusion methods [15]. The tested GNB were classified as susceptible or resistant (including intermediate) strains as recommended by CLSI (previous NCCLS) [16]. Interpretations of MICs of tigecycline against Acinetobacter spp. were based on the US-FDA susceptibility breakpoints for Enterobacteriaceae [17]. Data concerning HAI were expressed as incidence density per 1,000 patient-days/quarter.

Consumptions of each individual antibiotic and incidence of HAI were first evaluated for trend over time using Box-Jenkins autoregressive-integrated-moving average (ARIMA) modeling method [18,19]. ARIMA models were fit for every series using the standard approach of identification, estimation, and checking. All the series are stationary as were confirmed by augmented Dickey-Fuller tests. The autocorrelation, partial autocorrelation, and inverse autocorrelation functions were used to exclude serial dependencies and to ensure appropriateness of the model. A transfer function was estimated, and an ARIMA model was fit to the remaining noise. Akaike’s information criterion was used to identify the appropriate model by minimizing both the residual
variance and the number of parameters [19]. A trend was regarded as statistically significant when a $P$ was $<0.05$; otherwise, it was considered stable.

The presence or absence of associations between selected clinically meaningful antibiotic resistance and consumption series was further explored in pairs using cross-correlation analysis [20], where quarterly time lags of up to one year in both directions (i.e., time lag of $-4$ to $4$) were applied to the antibiotic resistance series [20], and the strength of association was measured by a nonparametric Spearman coefficient. An association was considered significantly present at any quarterly time lag when a $P$ was $<0.05$ and a correlation coefficient $R$ was $\geq 0.6$ or $\leq -0.6$. The highest correlation coefficient for each pair of specific antibiotic consumption and selected clinically meaningful antibiotic resistance determined the most likely positive time lag where the consumption of this antibiotic led to the development of antibiotic resistance or vice versa for that particular pair. A negative time lag for any result indicated that the antibiotic resistance had preceded the consumption of a specific antibiotic and vice versa for a positive time lag. All statistical analyses were performed using SAS software version 9.2 for Window (SAS Institute, Inc., Cary, NC, USA).

Results

The trends in antibiotic consumptions and the HAI incidence during 2002 and 2009 are summarized in Table 1. We found (i) increasing trends in consumptions of extended-spectrum cephalosporins, carbapenems, fluoroquinolones, aminopenicillins/$\beta$-lactamase inhibitors, and piperacillin/tazobactam, (ii) decreasing trends in the consumptions of non-extended spectrum cephalosporins, natural penicillins, aminopenicillins, ureidopenicillins, folye pathway inhibitors and aminoglycosides, (iii) stable trend of consumption of glycopeptides, (iv) decreasing trends in overall antibiotic consumptions and selected clinically meaningful antibiotic resistance and consumption series (Table 2). The presence or absence of associations between selected clinically meaningful antibiotic resistance and consumption series was further explored in pairs using cross-correlation analysis [20], where quarterly time lags of up to one year in both directions (i.e., time lag of $-4$ to $4$) were applied to the antibiotic resistance series [20], and the strength of association was measured by a nonparametric Spearman coefficient. An association was considered significantly present at any quarterly time lag when a $P$ was $<0.05$ and a correlation coefficient $R$ was $\geq 0.6$ or $\leq -0.6$. The highest correlation coefficient for each pair of specific antibiotic consumption and selected clinically meaningful antibiotic resistance determined the most likely positive time lag where the consumption of this antibiotic led to the development of antibiotic resistance or vice versa for that particular pair. A negative time lag for any result indicated that the antibiotic resistance had preceded the consumption of a specific antibiotic and vice versa for a positive time lag. All statistical analyses were performed using SAS software version 9.2 for Window (SAS Institute, Inc., Cary, NC, USA).

Discussion

Our report explored the relationships among HAI, MDR-GNB HAI, and antibiotic consumptions, and provided insight into time lags regarding the emergence of HAI due to CR-Acinetobacter spp. and consumption of piperacillin/tazobactam could be found in the time lags of $-3$, $-2$, $-1$ and the zero time lag (Table 3).

In this series, non-extended cephalosporins, natural penicillins, aminopenicillins, ureidopenicillins and aminoglycosides were consumed less, and these antibiotics were negatively correlated with the increasing trend of HAI caused by CR-Acinetobacter spp. The escalating trend of antibiotic resistance, pharmaceutical marketing practice, and changing physician perceptions may have contributed to the reduced consumptions of non-extended cephalosporins, and aminoglycosides. Potential side effects such as ototoxicity and renal toxicity may have been additional cause of the decline in the prescription of aminoglycosides. Because of the current high prevalence of antimicrobial-resistance [29], the usefulness of non-extended cephalosporins may be limited in the treatment of infections caused by GNB. However, our data suggests the need for strengthening the role of aminoglycosides in these circumstances. Aminoglycosides are reported to have a comparatively stable susceptibility rate among GNB that are acquired from either
community or nosocomial sources [30,31]. One study from a medical center disclosed that the empirical combined use of an anti-pseudomonal antibiotic (e.g., ceftazidime, cefpirome, cefepime, piperacillin/tazobactam, imipenem, or meropenem) and an aminoglycoside (i.e., gentamicin or amikacin) covered 85%–95% of the GNB isolated from the blood of neutropenic cancer patients [31], and another study suggested that patients with recent exposure to gentamicin or amikacin are at lower risk for acquiring bacteremia caused by *K. pneumoniae* isolates that simultaneously harbors plasmid-mediated ESBL and AmpC β-lactamase [32].

| Table 1. Trends in antibiotic consumption (DDD/1,000 inpatient-days/quarter) and incidences of healthcare-associated infections (events/1,000 inpatient-days/quarter) from 2002 to 2009 at KSCGMH. |
|--------------------------------------------------------------------------------------------------|
| **Antibiotic consumption**                                                                       |
| Mean    | Coefficient | P value | Transformation | AR or MA* (order b) | R²    | Trend c |
|---------|------------|---------|----------------|---------------------|-------|---------|
| Non-extended-spectrum cephalosporins       | 184.9     | -3.17   | <0.01          |                     | 0.95  | Decreasing |
| Extended-spectrum cephalosporins            | 67.8      | 0.96    | <0.01          |                     | 0.83  | Increasing |
| Aminoglycosides                             | 62.2      | -0.02   | 0.01           | Log                 | AR (1) | 0.99     | Decreasing |
| Natural penicillin and aminopenicillins      | 10.0      | -0.03   | <0.01          | Log                 | AR (1) | 0.74     | Decreasing |
| Ureidopenicillins                           | 117.2     | < -0.01 | 0.05           | Log                 | AR (1), MA (2) | 0.72 | Decreasing |
| Carbapenems                                  | 23.8      | 0.75    | <0.01          | AR (1)              | 0.76  | Increasing |
| Fluoroquinolones                             | 39.9      | 0.96    | <0.01          |                     | 0.72  | Increasing |
| Glycopeptides                                | 35.2      | -0.02   | 0.81           |                     | <0.01 | Stable |
| Folate pathway inhibitors                    | 24.4      | -0.02   | <0.01          | Log                 | 0.83  | Decreasing |
| Aminopenicillins/β-lactamase inhibitors      | 59.4      | 1.40    | <0.01          | AR (1)              | 0.83  | Increasing |
| Piperacillin/tazobactam                      | 7.5       | 0.47    | <0.01          |                     | 0.7   | Increasing |
| Overall antibiotics                          | 725.8     | -3.83   | <0.01          |                     | 0.65  | Decreasing |

| **Incidence**                                  |
|------------------------------------------------|
| Overall HAI s                                 |
| Mean    | Coefficient | P value | Transformation | AR or MA* (order b) | R²    | Trend c |
|---------|------------|---------|----------------|---------------------|-------|---------|
| Non-extended-spectrum cephalosporins       | 4.68      | -0.03   | <0.01          |                     | 0.31  | Decreasing |
| Extended-spectrum cephalosporins            | 2.65      | -0.02   | <0.01          |                     | 0.25  | Stable |
| Aminoglycosides                             | 0.98      | -0.01   | 0.01           |                     | 0.2   | Stable |

Abbreviation: DDD = defined daily dose; HAI: healthcare associated infection; GNB: Gram-negative bacilli; MDR: multidrug-resistant.

*AR, autoregressive, representing the past values of the quarterly incidence; MA, moving average, representing the past variance of the quarterly observations.

Delay in quarters before the effect is observed.

A significant trend referred to that with a $R^2 > 0.3$ and $P < 0.05$.

doi:10.1371/journal.pone.0065621.t001

| Table 2. Numbers of healthcare-associated infection (HAI) and the pathogenic Gram-negative bacilli from 2002 to 2009 at KSCGMH. |
|------------------------------------------------------------------------------------------------|----------|
| **HAI**                                    | **Pathogens** |
| **Acinetobacter spp.**                      | **E. coli** | **K. pneumoniae** | **P. aeruginosa** | **Others** | **Subtotal, n (%)** |
| BSI                                           | 228       | 499       | 417       | 277    | 715    | 2136 (17.0%) |
| CLABSI                                          | 212       | 75        | 83        | 177    | 196    | 743 (5.9%)   |
| GI                                               | 22        | 47        | 38        | 25     | 95     | 227 (1.8%)   |
| Pneumonia                                       | 316       | 57        | 148       | 343    | 287    | 1151 (2.3%)  |
| SSI                                              | 122       | 319       | 194       | 346    | 702    | 1683 (13.4%) |
| SST                                              | 27        | 32        | 32        | 51     | 73     | 215 (1.7%)   |
| UTI                                             | 483       | 2613      | 801       | 1070   | 1324   | 6291 (50.1%) |
| Miscellaneous!                                  | 22        | 11        | 16        | 51     | 21     | 121 (1.0%)   |
| Subtotal, n (%)                                 | 1432      | 3653      | 1729      | 2340   | 3413   | Total, N = 12567 |

Abbreviations: BSI: bloodstream infection; CLABSI: central-line associated bloodstream infection; GI: gastrointestinal system infection; SSI: surgical site infection; SST: skin and soft tissue infection; UTI: urinary tract infection.

*Derived from n/N X 100.

Including K. oxytoca, Enterobacter cloacae, Senataea marcescens, Proteus spp., Stenotrophomonas maltophilia, and other glucose-nonfermenting GNB (such as P. fluorescens, P. putida, Burkholderia cepacia, Chryseobacterium meningosepticum, C. indolgenes, and Alcaligenes spp.).

Including bone and joint infection, cardiovascular system infection, central nervous system infection, eye, ear, nose, throat or mouth infection, and reproductive tract infection.

doi:10.1371/journal.pone.0065621.t002
As HAIs caused by CR-\textit{Acinetobacter} spp. escalate, clinicians must resort to broader-spectrum or newer antibiotics, furthering the vicious circle of increasing antibiotic resistance and demand for more effective antibiotic coverage for drug-resistant microbes, eventually resulting in the disastrous consequence of lacking effective antibiotics for MDR pathogens [1]. One limitation of this series is that DDD measurements did not assess antibiotic exposure at the level of individual patients where antibiotic selective pressure typically occurs [33], although the DDD measurements of antibiotic consumption are useful for comparison and benchmarking. In addition, this study was conducted at a single medical centre with its specific medical practice, infection control program and antibiotic prescribing patterns, and may therefore limit the generalizability when it comes to data interpretations.

Table 3. Correlations of antibiotic consumptions and healthcare-associated infections caused by carbapenem-resistant \textit{Acinetobacter} spp. per 1,000 patient-days per quarter (2002 to 2009) and time lag effects of antibiotic consumptions.

| Antibiotic                                    | Time lag effect |
|-----------------------------------------------|-----------------|
|                                               | −4  −3  −2  −1  0  1  2  3  4 |
|                                               | R  P  R  P  R  P  R  P  R  P  R  P  R  P  R  P |
| Non-extended-spectrum cephalosporins          | −0.92 <0.1 −0.87 <0.1 −0.88 <0.1 −0.88 <0.1 −0.93 <0.1 −0.94 <0.1 −0.91 <0.1 −0.91 <0.1 −0.89 <0.1 |
| Extended-spectrum cephalosporins              | 0.84 <0.01 0.78 <0.01 0.77 <0.01 0.83 <0.01 0.86 <0.01 0.82 <0.01 0.85 <0.01 0.83 <0.01 0.84 <0.01 |
| Aminoglycosides                               | −0.91 <0.01 −0.91 <0.01 −0.93 <0.01 −0.92 <0.01 −0.93 <0.01 −0.92 <0.01 −0.91 <0.01 −0.91 <0.01 |
| Natural penicillins and aminopenicillins      | −0.67 <0.01 −0.77 <0.01 −0.78 <0.01 −0.79 <0.01 −0.85 <0.01 −0.81 <0.01 −0.81 <0.01 −0.78 <0.01 |
| Ureidopenicillins                             | −0.56 <0.01 −0.51 <0.01 −0.53 <0.01 −0.50 <0.01 −0.63 <0.01 −0.62 <0.01 −0.74 <0.01 −0.79 <0.01 |
| Carbenepens                                   | 0.72 <0.01 0.67 <0.01 0.74 <0.01 0.77 <0.01 0.79 <0.01 0.82 <0.01 0.76 <0.01 0.74 <0.01 0.71 <0.01 |
| Fluoroquinolones                              | 0.83 <0.01 0.87 <0.01 0.81 <0.01 0.82 <0.01 0.79 <0.01 0.74 <0.01 0.71 <0.01 0.68 <0.01 0.74 <0.01 |
| Glycopeptides                                 | 0.09 0.65 −0.04 0.85 0.08 0.69 −0.02 0.89 0.13 0.49 0.09 0.60 0.04 0.84 −0.02 0.91 −0.05 0.79 |
| Folate pathway inhibitors                     | −0.85 <0.01 −0.79 <0.01 −0.87 <0.01 −0.83 <0.01 −0.86 <0.01 −0.86 <0.01 −0.86 <0.01 −0.88 <0.01 |
| Aminopenicillins/β-lactamase inhibitors       | 0.77 <0.01 0.75 <0.01 0.72 <0.01 0.76 <0.01 0.83 <0.01 0.78 <0.01 0.69 <0.01 0.76 <0.01 0.72 <0.01 |
| Piperacillin/tazobactam                       | 0.15 0.62 0.64 0.02 0.74 <0.01 0.59 0.02 0.63 <0.01 0.40 0.11 0.40 0.11 0.55 0.02 0.53 0.03 |
| Overall antibiotics                           | −0.74 <0.01 −0.76 <0.01 −0.78 <0.01 −0.75 <0.01 −0.78 <0.01 −0.76 <0.01 −0.79 <0.01 −0.83 <0.01 |

Figure 1. The resistance proportion of healthcare-associated infections caused by multidrug-resistant Gram-negative bacilli from 2002 to 2009. Abbreviations: CR = carbapenems resistant; GNB = Gram-negative bacilli; MDR = multidrug-resistant; Q = quarter. doi:10.1371/journal.pone.0065621.g001
In summary, our data demonstrated lacking significant association between the development of HAIs caused by *CR-Acinetobacter* spp. and the increased use of piperacillin-tazobactam, an antibiotic reported to have fewer negative impacts on microbiological ecology in hospitals [24—27,32]. In addition, the results suggested antibiotic regimens with an aminoglycoside may help improve the incidence of HAIs due to *CR-Acinetobacter* spp.. Given that the trend in overall HAIs decreased and trends in GNB HAIs and MDR-GNB HAIs remained stable, suggesting the effectiveness of infection control practice during the study period, the association of antibiotic consumptions and increasing HAIs caused by *CR-Acinetobacter* spp. underscores that the importance of antibiotic stewardship in the improvement of the trend of HAIs due to *Acinetobacter* spp. cannot be overemphasized.

### Author Contributions

Conceived and designed the experiments: ILC CHL JWL. Performed the experiments: ILC CHL LHS YFT. Analyzed the data: ILC CHL LHS YFT SJG. Wrote the paper: ILC CHL JWL.

### References

1. Roucher HW, Talbot GH, Bradley JS, Edwards JR, Gilbert D, et al. (2009) Bad Bugs, No Drugs: no ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1–12.

2. Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197: 1079–1081.

3. Rosenhal VD, Malik DG, Janmahal S, Medeiros EA, Toli SK, et al. (2010) International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 38: 95–104.

4. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant *Gram*-negative bacilli. Antimicrob Agents Chemother 52: 813–821.

5. Hsueh PR, Chen WH, Luh KT (2005) Relationships between antimicrobial use and antimicrobial resistance in *Gram*-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan. Int J Antimicrob Agents 26: 463–472.

6. van de Sande-Bruinsma N, Grandmann H, Verloo D, Tiemersma E, Mouden J, et al. (2008) Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 14: 1722–1730.

7. Lai CC, Wang CY, Chu CC, Tan CK, Lu CL, et al. (2011) Correlation between antibiotic consumption and resistance of *Gram*-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. J Antimicrob Chemother 66: 1374–1382.

8. Metz-Gercek S, Maieron A, Strauss R, Wienerberger P, Apfalter P, et al. (2009) Ten years of antibiotics consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis 9: 61.

9. Murri A, Threlfall EJ, Jones RN (2004) Antimicrobial usage and resistance trend relationship from MYSTIC programme in North America (1999-2001). J Antimicrob Chemother 53: 290–296.

10. Cook PP, Cattou PG, Christie JD, Young PD, Polk RE (2004) Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiotic usage. J Antimicrob Chemother 53: 853–859.

11. WHO Collaborating Centre for Drug Statistics Methodology (2005) Guidelines for ATC classification and DDD Assignment. Oslo: WHO.

12. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) CDC definitions for nosocomial infection, 1988. Am J Infect Control 16:128–140.

13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definition for acquired resistance. Clin Microbiol Infect 18: 268–281.

14. Pezzlo M (1998) Aerobic bacteriology. In: Isenberg HD ed. Essential procedures for clinical microbiology. Washington, DC: American Society for Microbiology. pp. 205–255.

15. Pezzlo M (1998) Aerobic bacteriology. In: Isenberg HD ed. Essential procedures for clinical microbiology. Washington, DC: American Society for Microbiology. pp. 205–255.

16. National Committee for Clinical Laboratory Standards (2002) Zone diameter interpretive standards and equivalent minimal inhibitory concentration (MIC) breakpoints for Enterobacteriaceae. Approved standard M2-A7. Villanova, PA: NCCLS.

17. Liu JW, Jiang TN, Cheng YJ, Hsu GJ, Sun W et al. (2010) Comparison of the Etest and broth microdilution method for tigecycline susceptibility testing against clinical isolates of *Acinetobacter baumannii* from Taiwan. Int J Antimicrobial Agents 35: 201–202.

18. Helfenstein U (1996) Box-Jenkins modelling in medical research. Stat Methods Med Res 5: 3–22.

19. Helfenstein U (1991) The use of transfer function models, intervention analysis and related time series methods in epidemiology. Int J Epidemiol 20: 808–815.

20. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M (2002) Consumption of imipenem correlates with beta-lactam resistance in *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 46: 2920–2925.

21. White RL, Friedrich LV, Mihm LB, Bosso JA (2000) Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas. Clin Infect Dis 31: 16–23.

22. Warren DF, Fraser VJ (2001) Infection control measures to limit antibiotic resistance. Crit Care Med (suppl 6): N128–134.

23. Neuhaus MM, Weinstein RA, Rydman R, Danziger LH, Karam G, et al. (2003) Antibiotic resistance among *gram*-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 290: 885–888.

24. Rice LB, Eckstein GC, DeVentre J, Shlaes DM (1996) Cefazidime-resistant *Klebsiella pneumoniae* isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 23: 118–124.

25. Banar C, Vesco E, Heit C, Salomone F, Krayski M, et al. (2004) Replacement of broad-spectrum cephalosporins by piperacillin/tazobactam: impact on sustained high rates of bacterial resistance. Antimicrob Agents Chemother 48: 392–395.

26. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH (2000) Association of antibiotic utilization measures and control of multiple-drug resistance in *Klebsiella pneumoniae*. Infection Control Hosp Epidemiol 21: 453–458.

27. Lam CK, Hsueh PR, Wong WW, Fung CP, Lau YT, et al. (2003) Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. J Microbiol Immunol Infect 36: 182–186.

28. Lee YT, Fung CP, Wang FD, Chen CP, Chen TL, et al. (2012) Outbreak of imipenem-resistant *A. calcoaceticus*-*A. baumannii* complex harboring different carbapenemase gene-associated genetic structures in an intensive care unit. J Microbiol Immunol Infect 45: 43–51.

29. Liu JW, Ko WC, Huang CH, Liao CH, Lu CT, et al. (2012) Antimicrobial consumption and MDR-GNB HAI trends from Taiwan. Int J Antimicrob Agents 39: 35–45.

30. Liu JW, Ko WC, Huang CH, Liao CH, Lu CT, et al. (2012) Antimicrobial consumption and MDR-GNB HAI trends from Taiwan. Int J Antimicrob Agents 41: 270–273.

31. Huang CC, Wu CJ, Wang LD, Lee HC, Chang CM, et al. (2011) Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan. J Microbiol Immunol Infect 44: 376–381.

32. Lee CH, Su LH, Li CC, Chien CC, Tang YF, et al. (2010) Microbiologic and clinical implications of bacteremia due to extended-spectrum-β-lactamase-producing *Klebsiella pneumoniae* with or without plasmid-mediated AmpC β-lactamase DHA-1. Antimicrob Agents Chemother 54: 3595–3598.

33. Turndige J, Christiansen K (2005) Antibiotic use and resistance—proving the obvious. Lancet 365: 540–549.